DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO

Home/Compounds/ARA-290

HealingRx required

ARA-290

Also known as: Cibinetide

Investigational 11-amino-acid peptide derived from erythropoietin helix B; studied for tissue protection.

Ask AI about ARA-290 Find a clinic

Grade B

Human observational studies

Human studies27

PubMed citations30

Routesubcutaneous

Regulatory (US)Rx required

Last verified2 days ago

Mechanism of action

Binds the innate repair receptor (EPOR/βcR heterodimer), activating tissue-protective and anti-inflammatory pathways without stimulating erythropoiesis.

Evidence summary

Human studies

PubMed citations

Clinical trials

Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.

Administration routes

subcutaneous

Side effects & safety

No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.

Interactions

No documented drug interactions on file.

Regulatory status

United States

Not FDA approved

Investigational — studied for sarcoidosis neuropathy and diabetic peripheral neuropathy.

Compounding

Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT06626971A Phase II Clinical Trial on the Use of ARA 290 for the Treatment of Diabetic Macular OedemaTerminated · Phase 2 · Diabetic Macular Oedema · n=9 NCT02039687A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisCompleted · Phase 2 · Neuropathy of Sarcoidosis · n=64 NCT01933529Effects of ARA 290, a Non-hematopoietic Erythropoietin Analogue, on Glucose Tolerance, Insulin Secretion, Insulin Sensitivity and Long-term Glucose Control in Individuals With Prediabetes and/or Drug-naive Type 2 Diabetes; a Phase II Study.Unknown · Phase 2 · Diabetes Type 2 · n=24 NCT02070783The Effects of ARA290 on the Cognitive and Neural Processing of Emotions in Healthy VolunteersCompleted · Phase 1 · Depression · n=36

Citations

PMID 41659975Sun Y, Song B et al. · Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy.Frontiers in neurology (2026)Human PMID 36741836Winicki NM, Nanavati AP et al. · A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan.Frontiers in cardiovascular medicine (2023)Human PMID 36085231Ghassemi-Barghi N, Ehsanfar Z et al. · Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways.Inflammation (2023)Human PMID 34343617Al-Onaizi MA, Thériault P et al. · Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.Brain, behavior, and immunity (2022)Human PMID 35008482Awida Z, Bachar A et al. · The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice.International journal of molecular sciences (2022)Human PMID 35317117Mohtavinejad N, Hajiramezanali M et al. · Synthesis and evaluation of 99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region.Iranian journal of basic medical sciences (2022)Human PMID 33423557Rendell MS · The time to develop treatments for diabetic neuropathy.Expert opinion on investigational drugs (2021)Human PMID 32335150Shokrzadeh M, Etebari M et al. · An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress.Toxicology in vitro : an international journal published in association with BIBRA (2021)Human PMID 34498509Yao M, Domogatskaya A et al. · Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation.Cell transplantation (2021)Human PMID 32345869Yao M, Watanabe M et al. · Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand.Transplantation (2021)Human PMID 30876881O'Leary OE, Canning P et al. · The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic.Experimental eye research (2020)Human PMID 32674280Lois N, Gardner E et al. · A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.Journal of clinical medicine (2020)Human PMID 29026145Nairz M, Haschka D et al. · Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.Scientific reports (2019)Human PMID 27507833Atkins C, Wilson AM · Managing fatigue in sarcoidosis - A systematic review of the evidence.Chronic respiratory disease (2018)Human PMID 28941172Thomas A, Knoop A et al. · Characterization of in vitro generated metabolites of selected peptides <2 kDa prohibited in sports.Drug testing and analysis (2018)Human PMID 29223734Bitto A, Irrera N et al. · Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.Biochimica et biophysica acta. Molecular basis of disease (2018)Human PMID 28475703Culver DA, Dahan A et al. · Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Investigative ophthalmology & visual science (2017)Human PMID 26578461Thomas A, Görgens C et al. · Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science (2016)Human PMID 26774587Zhang W, Yu G et al. · ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.Peptides (2016)Human PMID 26683514Watanabe M, Lundgren T et al. · A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.Transplantation (2016)

Showing 20 of 30 papers. View all on PubMed →